Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates a steady flow of news across diagnostics, medical devices, nutritionals and branded generic medicines, reflecting its role as a global healthcare company serving people in more than 160 countries. News coverage on this page highlights regulatory milestones, product launches, clinical data, corporate actions and community initiatives that shape Abbott’s business and its impact on patients.
Recent announcements include FDA approvals and clearances for cardiovascular and structural heart technologies, such as the Volt PFA System for treating atrial fibrillation and the Amplatzer Piccolo Delivery System for minimally invasive closure of patent ductus arteriosus in premature infants. Abbott also reports developments in diabetes care and metabolic health, including enhancements to its Libre app through the Libre Assist feature, which uses generative AI and continuous glucose monitoring data to help people living with diabetes understand how food choices may affect glucose levels, and the expansion of its Lingo over-the-counter continuous glucose monitor to additional mobile platforms.
Investors and observers will also find news about Abbott’s nutrition business, such as new Ensure Max Protein shakes aimed at supporting muscle health for active and older adults, as well as information on public health partnerships and community programs like the "We Give Blood" competition with the Big Ten Conference and the HeartMates community for people with heart health challenges. Corporate updates include dividend declarations and increases, as well as the announced Agreement and Plan of Merger to acquire Exact Sciences Corporation, which would expand Abbott’s presence in cancer screening and precision oncology diagnostics.
This news feed provides a centralized view of Abbott’s latest announcements, allowing readers to follow developments in its key business segments and understand how new products, regulatory events and strategic transactions may influence the company over time.
Abbott (NYSE: ABT) will announce its fourth-quarter 2021 financial results on January 26, 2022, prior to market opening. A live webcast of the earnings call is scheduled for 8 a.m. Central and will be available on Abbott's Investor Relations website. Abbott is a global healthcare leader with a diverse portfolio in diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries through its 109,000 employees.
Abbott (NYSE: ABT) announced FDA approval for expanded MRI compatibility of its Proclaim™ XR Spinal Cord Stimulation (SCS) System with Octrode™ leads. This new labeling reduces MRI restrictions, allowing lead tips to be placed anywhere on the spine and increasing radiofrequency power usage during scans. Patients will benefit from faster and higher-quality MRI scans, addressing significant challenges in imaging for those with implanted devices. This update improves access to MRI imaging for existing patients and enhances diagnoses for complex conditions.
Abbott (NYSE: ABT) will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8 a.m. Central time. Robert B. Ford, the CEO, will lead the presentation. A live webcast will be available on Abbott's Investor Relations website, with an archived version posted later that day. Abbott is recognized as a global healthcare leader, providing life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. The company serves over 160 countries with a workforce of 109,000 colleagues.
Abbott (NYSE: ABT) has appointed Robert B. Ford as the new Chairman of the Board, effective immediately, following the retirement of Miles D. White after 38 years with the company. The transition is expected to bolster Abbott’s leadership in health technology, with Ford committed to advancing the company's mission amidst ongoing opportunities in healthcare. White praised Abbott's transformation during his tenure, while Ford expressed gratitude for White's mentorship. Abbott operates globally in diagnostics, medical devices, nutritionals, and branded generic medicines.
Abbott has announced a 4.4% increase in its quarterly common dividend, raising it to 47 cents per share, marking the 50th consecutive year of dividend growth. This payment will be made on Feb. 15, 2022, to shareholders on record by Jan. 14, 2022. The company also authorized a new $5 billion share repurchase program, supporting its strategy for sustainable shareholder returns and innovation. Abbott boasts a history of 392 consecutive quarterly dividends and is a member of the S&P 500 Dividend Aristocrats Index.
Abbott (NYSE: ABT) has launched Similac 360 Total Care, the first U.S. infant formula featuring a unique blend of five human milk oligosaccharides (HMOs) to support overall baby health, immune system, and brain development. This formula addresses the needs of the nearly 75% of parents using infant formula within the first six months due to various reasons. With over 20 years of research on HMOs, Abbott aims to narrow the gap between breast milk and formula, offering parents a scientifically backed alternative to nourish their babies.
Summary not available.
Abbott (NYSE: ABT) announced positive data from the Leadless II study for its investigational Aveir leadless pacemaker, which showed an impressive 98% successful implantation rate among 200 patients. The device met primary safety and efficacy endpoints, with 96% of patients experiencing no serious adverse effects and 95.9% achieving effective pacing at six weeks post-implant. The findings were presented at the Asia Pacific Heart Rhythm Society's annual session and submitted for FDA review, signaling potential advancements in minimally invasive cardiac care.
Abbott and the American Diabetes Association have launched a community health partnership in Columbus, Ohio, targeting healthcare disparities for people of color living with diabetes. The initiative will educate and provide up to 150 Black adults with access to Abbott's FreeStyle Libre glucose monitoring technology. Black Americans face a 60% higher diabetes diagnosis rate and significant barriers to managing the disease effectively. This program aims to improve health outcomes and access to diabetes care technology.
Abbott reported strong financial results for Q3 2021, with sales reaching $10.9 billion, a 23.4% increase year-over-year. GAAP diluted EPS was $1.17, while adjusted diluted EPS grew 42.9% to $1.40. The company projects full-year diluted EPS of $3.55 to $3.65 and adjusted EPS of $5.00 to $5.10, indicating potential 38.4% growth. Significant product launches and acquisitions contributed to this growth, including FDA approvals for new medical devices and an acquisition of Walk Vascular.